myourlife.icu

Bioreactor is an engineered or manufactured vessel that is used in the production of wide range of biological products. Industrial bioreactor is a vessel in which biochemical process is carried out using microbes and animal cells or biologically active compounds that are derived from living cells. Bioreactors are cylindrical in shape with capacity of liters to cubic meters and is the most important component involved in bioprocessing. Fermentation processes such as wine, and beer production are carried out in bioreactors.

Click To Continue Reading @ Bioreactors Market

Bioreactors for large scale production of therapeutic products are made of stainless steel. In biopharmaceutical companies, small glass bioreactors are used for research and development purpose and for scale up activities. Another type of bioreactors are disposable bioreactors, which are meant for single use and hence are called as single-use bioreactors. It is generally used for extensive research and manufacturing. Bioreactors can operate in batch, fed batch, and continuous stirred tank processes. Bioreactors are used to produce therapeutics, which include monoclonal antibodies, vaccines, stem cells, and gene modified cells.

The efficiency of single-use bioreactors has increased across pharmaceutical industries in terms of production, quality control, and procurement. Single-use bioreactors offer advantages such as consistency in production, increase in speed of manufacturing, reduced operational cost, and reduction in manufacturing time of finished dosage form, which foster growth of bioreactors market. In 2016, as per the National Centre for Biotechnology Information (NCBI), operational cost per gram of monoclonal antibody production (mAb) for single-use bioreactor is around 22% lower than conventional system, mainly due to less labor, utilities, maintenance, and waste.

Key Vendors:

Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris, Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and Appplikon Biotechnology, Inc.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI.

Click To Continue Reading on Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

This infection is difficult for treatment due to increasing prevalence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp. ABSSSI market is expected to exhibit growth at a trajectory rate, owing to increasing number of patients suffering from these and large number of pipeline products, expected to receive approved in the forecast period.

The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received US FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.